Обзор материалов по саркоидозу, представленных на Конгрессе Европейского респираторного общества 2014 года
https://doi.org/10.18093/0869-0189-2014-0-5-123-128
Аннотация
Представлен обзор тезисов докладов по саркоидозу, опубликованных в материалах Конгресса Европейского респираторного общества (Мюнхен, 2014). Большинство работ было посвящено оценке механизмов развития воспаления при саркоидозе, генетической предрасположенности. Серия работ была посвящена имидждиагностике с акцентом на выявление кардиосаркоидоза посредством магнитно-резонансной томографии. В работах, посвященных лечению, обсуждалось снижение гормональной нагрузки на больных. Россия была представлена публикациями специалистов из Москвы, СанктПетербурга, Новосибирска.
Об авторах
И. Ю. Визель
ГБОУ ВПО "Казанский государственный медицинский университет" Минздрава России: 420012, Республика Татарстан, Казань, ул. Бутлерова, 49
Россия
Россия
к. м. н, профессор РАЕ, ассистент кафедры фтизиопульмонологии ГБОУ ВПО "Казанский ГМУ" Минздрава России; тел.: (843) 2798003
А. А. Визель
ГБОУ ВПО "Казанский государственный медицинский университет" Минздрава России: 420012, Республика Татарстан, Казань, ул. Бутлерова, 49
Россия
Россия
д. м. н., профессор, зав. кафедрой фтизиопульмонологии ГБОУ ВПО "Казанский ГМУ" Минздрава России;
тел.: (987) 2962599
Список литературы
1. Puscinska E., Nowinski A., GoljanGeremek A. et al. Mortality in sarcoidosis, results from one centre, long termobservational study. Eur. Respir. J. 2014; 44 (Suppl. 58): 468.
2. Sobiecka M., Bartosiewicz M., Lewandowska K. et al. Sarcoidosis related to interferon and ribavirin treatment of hepatitis C. Analysis of four cases. Eur. Respir. J. 2014; 44 (Suppl. 58): 467.
3. Catinon M., Chemarin C., Villard E. et al. Sarcoidosis and pulmonary dust: Mineralogical analysis (MA) and optical microscopy (OM). Eur. Respir. J. 2014; 44 (Suppl. 58): 472.
4. Papakosta D., Spyropoulos G., Domvri K. et al. Long termfollowup of Greek patients with pulmonary sarcoidosis. Relation to transforming growth factorbeta genetic profile. Eur. Respir. J. 2014; 44 (Suppl. 58): 784.
5. Peletidou S., Zifa E., Grammatikopoulos A., Malli F. et al. Mitochondrial tRNA gene mutations in patients with idiopathic pulmonary fibrosis (IPF) and sarcoidosis. Eur. Respir.J. 2014; 44 (Suppl. 58): 824.
6. Calender A., Pacheco Y., Lebecque S. et al. Comparative phenotype and BTNL2 polymorphism in familial and sporadic sarcoidosis in the French SARCFAM cohort. Eur. Respir. J. 2014; 44 (Suppl. 58): 1734.
7. Milman N., Van Overeem Hansen T., Skov Jensen M. Does the BTNL2 genotype influence the course of disease in Danish sarcoidosis patients? Eur. Respir. J. 2014; 44 (Suppl. 58): 3224.
8. Navratilova Z., Novosadova E., Krsjakova T. et al. Differential bronchoalveolar expression of candidate microRNAs in chronic obstructive pulmonary disease, asth ma bronchiale and pulmonary. Eur. Respir. J. 2014; 44 (Suppl. 58): 198.
9. Kishore A., Navratilova Z., Kolek V., Petrek M. Detection of exosomal miRNA in pulmonary sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 199.
10. Harlander M., Zupancic M., Salobir B., Tercelj M. Biomarkers in sarcoidois followup: Angiotensinconverting enzyme or chitotriosidase? Eur. Respir. J. 2014; 44 (Suppl. 58): 462.
11. VucinicMihailovic V., Sumarac Z., Jovanovic D. et al. Assessing sarcoidosis activity: Is serum chitotriosidase a reliable marker? Study of 430 patients and 264 healthy controls. Eur. Respir. J. 2014; 44 (Suppl. 58): 1735.
12. Doubkova M., Karpisek M., Mazoch J. et al. Prognostic significance of selected biomarkers in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease. Eur. Respir. J. 2014; 44 (Suppl. 58): 471.
13. Bargagli E., Landi C., Carleo A. et al. Proteomic investigation of pulmonary sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 3878.
14. Lyamina S., Demyanenko N., Shelukhina S. et al. Functional phenotype of immune response and alveolarmacrophages phenotype in pulmonary sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 1476.
15. Osinska I., Wolosz D., Urbankowski T., DomagalaKulawik J. LSC 2014 abstract – M1/M2 subpopulations of macrophages in patients with sarcoidosis influence of smoking status. Eur. Respir. J. 2014; 44 (Suppl. 58): 1733.
16. Dubaniewicz A. Heat shock proteins as 'danger signals' in sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 3790.
17. Roussou A., Papaioannou A., Manali E.et al. Serum levels of sestrin 2 in patients with sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 3797.
18. Chandrashekariah S., Rosha D. Sarcoidosis in India: Investigation into vitamin D and calcium metabolism. Eur. Respir. J. 2014; 44 (Suppl. 58): 3777.
19. Kouranos V., Tzelepis G., Rapti A. et al. Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients. Eur. Respir. J. 2014; 44 (Suppl. 58): 463.
20. Tosun M., Keskin S., Akilli H. et al. Determination of cardiac involvement of sarcoidosis with cardiac MR, ECHO and Holter ECG. Eur. Respir. J. 2014; 44 (Suppl. 58): 470.
21. Stanton K., Ganigara M., Corte T. et al. The utility of cardiac magnetic resonance imaging in the diagnosis of cardiac sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 1728.
22. Kouranos V., Rapti A., Peros E. et al. Predictors of cardio vascular events in newly diagnosed patients with sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 474.
23. Papiris S., Georgakopoulos A., Pianou N. et al 18FFDG PET/CT for the evaluation of sarcoidosis patients. Eur. Respir. J. 2014; 44 (Suppl. 58): 657.
24. Dal Farra S., Picchio M., Incerti E. et al. Fluorine18fluo rodeoxyglucose positron emission tomography (18FFDG PET) may be useful in the management of sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 3222.
25. Menon B., Dogra V., Nima G. et al. Evaluation of thoracic HRCT findings in sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 664.
26. Hirche T.O., Hirche H., Cui X.W. et al. Ultrasound evaluation of mediastinal lymphadenopathy in patients with sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 671.
27. Marshall A., Ahmed L., Chalmers G. Experience of endobronchial ultrasound – transbronchial needle aspiration (EBUSTBNA) in granulomatous disease. Eur. Respir. J. 2014; 44 (Suppl. 58): 469.
28. Kameneva M., Syrtsova D., Baranova O.et al. A. Changes in lung mechanics and gas exchange in patients with pulmonary sarcoidosis (PS). Eur. Respir. J. 2014; 44 (Suppl. 58): 4271.
29. Karagiannis K., Bikov A., Bonifazi M. et al. Impulse oscillometry measurements are correlated to quality of life in patients with pulmonary sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 740.
30. Boros P., MartusewiczBoros M., Wesolowski S. Impact of smoking habit on lung function in a large cohort sarcoidosis patients. Eur. Respir. J. 2014; 44 (Suppl. 58): 475.
31. Karadalli M.N., Bosnak Guclu M., Camcioglu B. et al. Clinical determinants and chronotrophic responses of maximal exercise capacity in patients with early stage of sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 2158.
32. Laushkina Z. The analysis of factors associated with misdiagnosis sarcoidosis in TB hospital. Eur. Respir. J. 2014; 44 (Suppl. 58): 2676.
33. Nowinski A., Puscinska E., GoljanGeremek A. et al. Comorbidities associated with sarcoidosis – Results from longterm observational study. Eur. Respir. J. 2014; 44 (Suppl. 58): 461.
34. Nathan N., Marcelo P., Houdouin V. et al. Is pulmonary sarcoidosis more severe in children? A multicentric retrospective study. Eur. Respir. J. 2014; 44 (Suppl. 58): 465.
35. Güungör S., Yalçinsoy M., Usta Bülbül E. et al. Extrapulmonary involvement in sarcoidosis patients. Eur. Respir. J. 2014; 44 (Suppl. 58): 3751.
36. Romanov V. Atypical variants of clinical course of sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 3782.
37. Baranova O., Perlei V., Gichkin A. et al. Pulmonary embolism (PE) in patients with pulmonary sarcoidosis (PS). Eur. Respir. J. 2014; 44 (Suppl. 58): 4508.
38. Omcikus M., Vucinic V., Filipovic S., Videnovic J. Cognitive failure in sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 460.
39. MartusewiczBoros M., Boros P., Wiatr E., Roszkowski Sliz K. How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study. Eur. Respir. J. 2014; 44 (Suppl. 58): 464.
40. Grah C., Thieme C., Seiberth R. et al. Benefit of steroid free treatment compared to standard therapy (ST) in pulmonary sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 3765.
41. Goljan Geremek A., Bednarek M., Puscinska E. et al. Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis. Eur. Respir. J. 2014; 44 (Suppl. 58): 473.
42. Baranova O., Voinov V., Baklanova O. 30 years experience of plasmapheresis using in complex treatment of pulmonary sarcoidosis (PS). Eur. Respir. J. 2014; 44 (Suppl. 58): 4510.
43. Hostettler K., Baty F., Kleiner R. et al. Bosentan does not improve outcome in patients with steroidresistant pulmonary sarcoidosis – Results from a doubleblind placebo controlled phase 2 trial. Eur. Respir. J. 2014; 44 (Suppl. 58): 466.
Рецензия
Для цитирования:
Визель И.Ю., Визель А.А. Обзор материалов по саркоидозу, представленных на Конгрессе Европейского респираторного общества 2014 года. Пульмонология. 2014;(5):123-128. https://doi.org/10.18093/0869-0189-2014-0-5-123-128
For citation:
Vizel' I.Yu., Vizel' A.A. A review of data on sarcoidosis presented in the European Respiratory Society Congress 2014. PULMONOLOGIYA. 2014;(5):123-128. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-5-123-128
Просмотров:
1172
Послать статью по эл. почте 